[go: up one dir, main page]

EP0483309A1 - Solid support having antibodies immobilized thereon - Google Patents

Solid support having antibodies immobilized thereon

Info

Publication number
EP0483309A1
EP0483309A1 EP19910908038 EP91908038A EP0483309A1 EP 0483309 A1 EP0483309 A1 EP 0483309A1 EP 19910908038 EP19910908038 EP 19910908038 EP 91908038 A EP91908038 A EP 91908038A EP 0483309 A1 EP0483309 A1 EP 0483309A1
Authority
EP
European Patent Office
Prior art keywords
antibody
solid support
specific
nonspecific
immobilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19910908038
Other languages
German (de)
French (fr)
Inventor
Izak Bahar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PB Diagnostic Sytems Inc
Original Assignee
PB Diagnostic Sytems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PB Diagnostic Sytems Inc filed Critical PB Diagnostic Sytems Inc
Publication of EP0483309A1 publication Critical patent/EP0483309A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • G01N33/552—Glass or silica
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments

Definitions

  • This invention relates to solid supports having antibodies immobilized thereon and, more particularly, to such solid supports which are useful in solid phase immunoassays.
  • assay elements are known for use in immunoassays to analyze for analytes present in biological fluids.
  • one member of the antigen-antibody interaction pair e.g., the antibody
  • a solid carrier such as particulate materials, fibrous materials and the like.
  • the solid support becomes the site at which the interaction between the bound material and a binding partner takes place.
  • any of the known immunometric assays can be carried out in the solid phase format.
  • Such assays are well known to those skilled in the art. Briefly, for example, in the competitive assay a sample fluid containing an analyte of interest, e.g., an antigen, is applied to a solid support having bound thereto a binding partner of the analyte, e.g., an antibody. The amount of antibody bound to the support is that necessary to allow the requisite competition between the sample analyte and the labeled species.
  • a labeled analyte or a labeled analogue thereof is added to the solid support and after another incubation period and a wash step to remove any unbound labeled material, the bound labeled material is detected to provide a signal which is a function of the amount of analyte in the patient sample fluid.
  • the signal is inversely proportional to the amount of analyte in the sample.
  • the antibodies which are immobilized on the solid carrier can be bound thereto by various means including covalent binding, immunoprecipitation and the like.
  • the immunoprecipitation technique can be carried out more conveniently as compared to the chemical reaction(s) required for covalent binding.
  • assays such as the competitive immunoassay described previously, only a relatively limited amount of antibodies may be bound to the carrier because of various factors such as the assay concentration range, otc. If the binding technique employed is not efficient enough a low signal level may be obtained with a given amount of antibodies. Of course, the signal can be improved by adding more antibodies to the solid carrier but this alternative is not satisfactory if it results in the assay range being shifted outside of the range required for the analyte of interest.
  • the mouse monoclonal anti-digoxin antibodies are included in a complex together with an anti-mouse antibody which is raised against the Fc fragments of mouse antibodies and a mouse IgG antibody which is nonspecific.
  • the complex is immobilized on the solid support by passive adsorption.
  • the solid supports of the invention are prepared by initially mixing the antibody of interest, e.g., the anti-digoxin antibody, with the nonspecific antibody in a coating solution, typically a buffer solution, and then adding the specific antibody raised against the Fc fragments of the specific and nonspecific antibodies. The mixture is incubated under time and temperature conditions which allow the complex to form. The coating solution is applied to the solid support and the latter is dried.
  • the antibody complex is immobilized to the solid support through passive adsorption.
  • the solid supports of the invention have been found to be particularly advantageous when used in competitive solid phase immunoassays for the analysis of analytes in a sample fluid. Higher signal levels can be obtained while at the same time maintaining the sensitivity of the assay in the desired assay range.
  • the solid supports of the invention may comprise any suitable solid carrier such as, for example, particulate materials, porous members possessing an intercommunicating network of openings throughout such that a fluid deposited on the member will propagate through the member, and the like.
  • suitable porous members include porous membranes, fibrous mesh materials and the like and may be of any suitable material such as glass, polymeric materials, paper, etc.
  • the solid carrier is a thin fibrous mesh member which will permit fluid deposited thereon to propagate throughout because of capillary action.
  • the member may be any suitable fibrous material; a preferred material is a nonwoven glass fiber mesh, the fibers being very thin such as on the order of about 1 micrometer ( ⁇ m).
  • any monoclonal antibodies of interest may be immobilized on the solid carrier such as, for example, antibodies to: haptens such as digoxin, triiodothyronine (T3) and the like; proteins such as myoglobin; hormones; etc.
  • the nonspecific antibody may be any to which the antibody directed against the Fc fragments of the specific and nonspecific antibodies will bind.
  • the nonspecific antibody is of the same species as the specific antibody, i.e., they are both raised in the same type of host animal, e.g., mice.
  • the antibody which is raised against the Fc fragments of the specific and nonspecific antibodies can be raised in any host animal.
  • the coating solution which is used to apply the antibody complex to the solid support is prepared by initially combining the specific antibody of interest and the nonspecific antibody in an appropriate solution, preferably a buffer solution.
  • the solution may contain other additives such as, for example, proteins which are useful for reducing nonspecific binding, stabilizers such as sugars, surfactants which improve the wettability of the solid support and preservatives for preventing anti-microbial action.
  • the antibody directed against the Fc fragments of the specific and nonspecific antibodies is added.
  • the solution is then incubated under time and temperature conditions which are required to allow the complex formation to occur. These conditions will vary depending upon the specific materials, the amounts involved, etc. In a preferred embodiment the coating solution is incubated at 37°C for about one hour.
  • the solution is then deposited on the solid support and allowed to become immobilized thereon through passive adsorption.
  • the solid support is dried to provide a member which is useful in solid phase immunoassays.
  • the solid supports of the invention are utilized in the known competitive solid phase immunometric assays for an analyte of interest. Such assays are well known to those skilled in the art and extensive discussion thereof is not required here. To further describe the advantages of the solid supports of the invention their use in a preferred fibrous solid phase competitive immunoassay will be described.
  • an assay element 10 which includes a plurality of chambers in a housing 12 wherein a first chamber 14 serves as a front reservoir for the storage of a fluid reagent to be utilized in the assay, a second of the chambers serves as a back reservoir 16 for the storage of another fluid reagent for the assay, a third chamber 18 serves a mixing well for mixing reagents and fourth chamber 20 is adapted to dispense a fluid to one end of a porous solid support 22.
  • a chamber 24 within the housing 12 wherein there is arranged an absorbing material for absorbing fluid removed from solid support 22 such as by a wash fluid as the latter propagates through the fibrous solid support.
  • a frangible as puncturable foil (not shown) is disposed over the front and back reservoirs, 14 and 16, respectively, for containing the fluid reagents within these reservoirs thus providing a self contained assay element.
  • the solid support 22 in this preferred embodiment comprises a thin fibrous mesh pad to which there has been immobilized an antibody of interest in accordance with the invention.
  • a preferred solid support is a nonwoven glass fiber mesh having very thin fibers such as on the order of about 1 micrometer ( ⁇ m). This preferred solid support is from about 0.30 mm to about 0.60 mm in thickness, preferably about 0.40 mm.
  • the solid support 22 extends from the dispensing chamber 20 to the chamber 24 which holds the absorbing material.
  • the fluid absorbing material 26 which may be any suitable material, is located within chamber 24 and forms a part of the chamber 24 for taking up fluid expelled from the solid support and the guide area (not shown) in which the support is arranged.
  • the absorbing material 26 is located contiguous the solid support 22 and in a preferred embodiment, as illustrated, is formed conveniently as an extension of the solid support material folded back and forth on itself.
  • the housing 12 also includes a chamber 28 which is positioned immediately above the area of the solid support where the immunometric interactions take place. It will be apparent to those skilled in the art that the immobilized antibody complex bound to the solid support need only be present on that part of the support where the immunometric interactions will take place.
  • the housing 12 also preferably includes a transparent window (not shown) or an opening in the housing, positioned immediately below the bottom surface of the solid support 22 to provide access for the readout illumination used to measure the detectable change effected in the support as a result of the assay method.
  • a volume of sample fluid typically 30-45 ⁇ is deposited on the solid support 22 through chamber 28.
  • the sample fluid is allowed to incubate for a suitable period at the appropriate temperature to allow the sample antigen to interact with the immobilized antibodies in the reaction site on the solid support.
  • a conjugate of an enzyme-labeled antigen (the same as the sample antigen) or an analogue thereof is withdrawn from chamber 14 and deposited on the solid support through chamber 28.
  • the conjugate will bind to any specific antibodies on the solid support which are not bound to the sample antigen.
  • the assay element 10 is again allowed to incubate. Since the enzyme label must be detected indirectly, a substrate solution, typically 50-100 ⁇ is applied to the porous solid support 22 through chamber 20. The substrate solution is utilized both as a wash fluid to remove from the solid support any unbound sample antigen or conjugate and to render the enzyme label detectable.
  • the substrate solution is caused to enter an end portion of the solid support and as the solution propagates through the solid support 22 it forces any unbound sample antigen and enzyme conjugate together with the fluid out of the solid support and into the absorber chamber 24 where it is taken up by the absorber material 26.
  • the signal provided by the fluorescent species liberated by the reaction of the enzyme with the substrate material is read out by means of suitable optical apparatus.
  • EXAMPLE I An antibody solution was prepared containing 0.1 g/ml of anti-digoxin antibodies and 10 ⁇ g/ml of mouse IgG antibodies in a pH 7.2 phosphate buffered saline solution which also contained other proteins, stabilizers, surfactants and anti-microbial agents. The solution was filtered through a 0.2 ⁇ m filter and then 2 ml of a solution of Goat Anti-Mouse IgG, Fc Fragment Specific (Jackson ImmunoResearch) was diluted 1 : 100 with the antibody solution to form a coating solution.
  • the coating solution was incubated for one hour at 37°C and about 35 ⁇ added to an approximately 7 x 8 mm area of a Whatman GF/F fibrous glass filter material.
  • the filter material was dried for about 10 minutes at 75 °C and incorporated into an assay element as described previously.
  • the assay elements were then used to carry out the competitive immunometric assay method previously described with sample fluids containing known digoxin concentrations.
  • the assays were carried out on an automated laboratory instrument.
  • the enzyme label used in the conjugate was methyl umbelliferyl phosphate and the readout signal was obtained by directed 360 nm radiation upon the bottom surface of the solid support and measuring the reflected 450 nm radiation.
  • the signals obtained are shown in Table I.
  • the assays were read kinetically and the signals obtained are the slopes of the kinetic measurements. Each value shown in Table I is the average of three replicates.
  • the assay method of the invention provided high signal levels and a desirable steep standard curve slope in the assay range (about 0.5 - 4.0 ng/ml).
  • EXAMPLE II A coating solution was prepared which was the same as that described in Example I except that it contained 0.0625 / g/ml of a monoclonal antibody to T3 instead of the anti-digoxin antibodies. Assay elements were prepared as described in Example I and used to carry out the competitive solid phase assay method previously described. The results obtained are shown in Table II. Table II
  • the assay method of the invention provided high signal levels and a desirable steep standard curve slope in the assay range (about 0.50 - 8.00 ng/ml).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Support solide ayant des anticorps immobilisés sur sa surface. Les anticorps spécifiques et présentant un intérêt sont immobilisés sur le support solide en tant que partie d'un complexe comprenant un anticorps non spécifique et un anticorps s'opposant aux fragments Fc des anticorps spécifiques et non spécifiques. Dans un mode d'exécution préféré, on utilise le support solide dans des immunoanalyses compétitives en phase solide et il produit de meilleurs niveaux de signaux et des courbures recherchées de fortes pentes standard dans la plage de sensibilité recherchée de l'analyse.Solid support having antibodies immobilized on its surface. The specific antibodies of interest are immobilized on the solid support as part of a complex comprising a non-specific antibody and an antibody opposing the Fc fragments of the specific and non-specific antibodies. In a preferred embodiment, the solid support is used in competitive solid phase immunoassays and it produces better signal levels and desired curvatures of steep standard slopes within the desired sensitivity range of the analysis.

Description

SOLID SUPPORT HAVING ANTIBODIES IMMOBILIZED THEREON
BACKGROUND OF THE INVENTION This invention relates to solid supports having antibodies immobilized thereon and, more particularly, to such solid supports which are useful in solid phase immunoassays. Various types of assay elements are known for use in immunoassays to analyze for analytes present in biological fluids. In one type which is commonly referred to as a solid phase immunoassay, one member of the antigen-antibody interaction pair, e.g., the antibody, is bound to a solid carrier such as particulate materials, fibrous materials and the like. In these assays the solid support becomes the site at which the interaction between the bound material and a binding partner takes place.
Any of the known immunometric assays, e.g., sandwich or competitive assays, can be carried out in the solid phase format. Such assays are well known to those skilled in the art. Briefly, for example, in the competitive assay a sample fluid containing an analyte of interest, e.g., an antigen, is applied to a solid support having bound thereto a binding partner of the analyte, e.g., an antibody. The amount of antibody bound to the support is that necessary to allow the requisite competition between the sample analyte and the labeled species. Subsequently, after a period of incubation, a labeled analyte or a labeled analogue thereof is added to the solid support and after another incubation period and a wash step to remove any unbound labeled material, the bound labeled material is detected to provide a signal which is a function of the amount of analyte in the patient sample fluid. The signal is inversely proportional to the amount of analyte in the sample.
The antibodies which are immobilized on the solid carrier can be bound thereto by various means including covalent binding, immunoprecipitation and the like. The immunoprecipitation technique can be carried out more conveniently as compared to the chemical reaction(s) required for covalent binding. However, in some assays such as the competitive immunoassay described previously, only a relatively limited amount of antibodies may be bound to the carrier because of various factors such as the assay concentration range, otc. If the binding technique employed is not efficient enough a low signal level may be obtained with a given amount of antibodies. Of course, the signal can be improved by adding more antibodies to the solid carrier but this alternative is not satisfactory if it results in the assay range being shifted outside of the range required for the analyte of interest.
Accordingly, it would be desirable to have new solid supports having antibodies immobilized thereon. It would also be desirable to have such solid supports which could be used in competitive solid phase immunoassays to provide improved signal levels while at the same time exhibiting low nonspecific binding. SUMMARY OF THE INVENTION These and other objects and advantages are accomplished in accordance with the invention by providing a solid support having immobilized thereon a complex of a specific antibody of interest, a nonspecific antibody and an antibody directed against the Fc fragments of the specific and nonspecific antibodies. For example, consider a mouse monoclonal anti-digoxin antibody as the specific antibody of interest which is to be immobilized on a solid support for use in an immunoassay for digoxin. According to the invention the mouse monoclonal anti-digoxin antibodies are included in a complex together with an anti-mouse antibody which is raised against the Fc fragments of mouse antibodies and a mouse IgG antibody which is nonspecific. The complex is immobilized on the solid support by passive adsorption. The solid supports of the invention are prepared by initially mixing the antibody of interest, e.g., the anti-digoxin antibody, with the nonspecific antibody in a coating solution, typically a buffer solution, and then adding the specific antibody raised against the Fc fragments of the specific and nonspecific antibodies. The mixture is incubated under time and temperature conditions which allow the complex to form. The coating solution is applied to the solid support and the latter is dried. The antibody complex is immobilized to the solid support through passive adsorption.
The solid supports of the invention have been found to be particularly advantageous when used in competitive solid phase immunoassays for the analysis of analytes in a sample fluid. Higher signal levels can be obtained while at the same time maintaining the sensitivity of the assay in the desired assay range.
BRIEF DESCRIPTION OF THE DRAWING For a better understanding of the invention as well as other objects and further features thereof, reference is made to the following detailed description of the preferred embodiments thereof taken in conjunction with the accompanying drawing wherein the Figure is a simplified, isometric view of a preferred assay element in accordance with the invention.
DESCRIPTION OF THE PREFERRED EMBODIMENT The solid supports of the invention may comprise any suitable solid carrier such as, for example, particulate materials, porous members possessing an intercommunicating network of openings throughout such that a fluid deposited on the member will propagate through the member, and the like. Suitable porous members include porous membranes, fibrous mesh materials and the like and may be of any suitable material such as glass, polymeric materials, paper, etc. In a preferred embodiment the solid carrier is a thin fibrous mesh member which will permit fluid deposited thereon to propagate throughout because of capillary action. The member may be any suitable fibrous material; a preferred material is a nonwoven glass fiber mesh, the fibers being very thin such as on the order of about 1 micrometer (μm). Any monoclonal antibodies of interest may be immobilized on the solid carrier such as, for example, antibodies to: haptens such as digoxin, triiodothyronine (T3) and the like; proteins such as myoglobin; hormones; etc. The nonspecific antibody may be any to which the antibody directed against the Fc fragments of the specific and nonspecific antibodies will bind. Preferably the nonspecific antibody is of the same species as the specific antibody, i.e., they are both raised in the same type of host animal, e.g., mice. The antibody which is raised against the Fc fragments of the specific and nonspecific antibodies can be raised in any host animal.
The coating solution which is used to apply the antibody complex to the solid support is prepared by initially combining the specific antibody of interest and the nonspecific antibody in an appropriate solution, preferably a buffer solution. The solution may contain other additives such as, for example, proteins which are useful for reducing nonspecific binding, stabilizers such as sugars, surfactants which improve the wettability of the solid support and preservatives for preventing anti-microbial action. Subsequently, the antibody directed against the Fc fragments of the specific and nonspecific antibodies is added. The solution is then incubated under time and temperature conditions which are required to allow the complex formation to occur. These conditions will vary depending upon the specific materials, the amounts involved, etc. In a preferred embodiment the coating solution is incubated at 37°C for about one hour.
The solution is then deposited on the solid support and allowed to become immobilized thereon through passive adsorption. The solid support is dried to provide a member which is useful in solid phase immunoassays.
In a preferred embodiment the solid supports of the invention are utilized in the known competitive solid phase immunometric assays for an analyte of interest. Such assays are well known to those skilled in the art and extensive discussion thereof is not required here. To further describe the advantages of the solid supports of the invention their use in a preferred fibrous solid phase competitive immunoassay will be described. Referring now to the
Figure there is seen an assay element 10 which includes a plurality of chambers in a housing 12 wherein a first chamber 14 serves as a front reservoir for the storage of a fluid reagent to be utilized in the assay, a second of the chambers serves as a back reservoir 16 for the storage of another fluid reagent for the assay, a third chamber 18 serves a mixing well for mixing reagents and fourth chamber 20 is adapted to dispense a fluid to one end of a porous solid support 22. There is also shown a chamber 24 within the housing 12 wherein there is arranged an absorbing material for absorbing fluid removed from solid support 22 such as by a wash fluid as the latter propagates through the fibrous solid support. A frangible as puncturable foil (not shown) is disposed over the front and back reservoirs, 14 and 16, respectively, for containing the fluid reagents within these reservoirs thus providing a self contained assay element. The solid support 22 in this preferred embodiment comprises a thin fibrous mesh pad to which there has been immobilized an antibody of interest in accordance with the invention. A preferred solid support is a nonwoven glass fiber mesh having very thin fibers such as on the order of about 1 micrometer (μm). This preferred solid support is from about 0.30 mm to about 0.60 mm in thickness, preferably about 0.40 mm. The solid support 22 extends from the dispensing chamber 20 to the chamber 24 which holds the absorbing material. The fluid absorbing material 26, which may be any suitable material, is located within chamber 24 and forms a part of the chamber 24 for taking up fluid expelled from the solid support and the guide area (not shown) in which the support is arranged. The absorbing material 26 is located contiguous the solid support 22 and in a preferred embodiment, as illustrated, is formed conveniently as an extension of the solid support material folded back and forth on itself. The housing 12 also includes a chamber 28 which is positioned immediately above the area of the solid support where the immunometric interactions take place. It will be apparent to those skilled in the art that the immobilized antibody complex bound to the solid support need only be present on that part of the support where the immunometric interactions will take place. The housing 12 also preferably includes a transparent window (not shown) or an opening in the housing, positioned immediately below the bottom surface of the solid support 22 to provide access for the readout illumination used to measure the detectable change effected in the support as a result of the assay method.
In the assay method a volume of sample fluid, typically 30-45 μ\ is deposited on the solid support 22 through chamber 28. The sample fluid is allowed to incubate for a suitable period at the appropriate temperature to allow the sample antigen to interact with the immobilized antibodies in the reaction site on the solid support.
Subsequently, a conjugate of an enzyme-labeled antigen (the same as the sample antigen) or an analogue thereof is withdrawn from chamber 14 and deposited on the solid support through chamber 28. The conjugate will bind to any specific antibodies on the solid support which are not bound to the sample antigen. The assay element 10 is again allowed to incubate. Since the enzyme label must be detected indirectly, a substrate solution, typically 50-100 μ\ is applied to the porous solid support 22 through chamber 20. The substrate solution is utilized both as a wash fluid to remove from the solid support any unbound sample antigen or conjugate and to render the enzyme label detectable. The substrate solution is caused to enter an end portion of the solid support and as the solution propagates through the solid support 22 it forces any unbound sample antigen and enzyme conjugate together with the fluid out of the solid support and into the absorber chamber 24 where it is taken up by the absorber material 26. The signal provided by the fluorescent species liberated by the reaction of the enzyme with the substrate material is read out by means of suitable optical apparatus.
It has been found that such competitive assays carried out with the solid supports of the invention provide higher signal levels and desirably steeper standard curve slopes in the assay range.
Although the preferred competitive solid phase assay has been described with respect to a sequential format it should be recognized that it can also be carried out in the simultaneous mode. The invention will now be described further in detail with respect to specific preferred embodiments by way of examples it being understood that these are intended to be illustrative only and the invention is not limited to the materials, conditions, process parameters, etc. which are recited therein.
EXAMPLE I An antibody solution was prepared containing 0.1 g/ml of anti-digoxin antibodies and 10 μg/ml of mouse IgG antibodies in a pH 7.2 phosphate buffered saline solution which also contained other proteins, stabilizers, surfactants and anti-microbial agents. The solution was filtered through a 0.2 μm filter and then 2 ml of a solution of Goat Anti-Mouse IgG, Fc Fragment Specific (Jackson ImmunoResearch) was diluted 1 : 100 with the antibody solution to form a coating solution.
The coating solution was incubated for one hour at 37°C and about 35 μ\ added to an approximately 7 x 8 mm area of a Whatman GF/F fibrous glass filter material. The filter material was dried for about 10 minutes at 75 °C and incorporated into an assay element as described previously.
The assay elements were then used to carry out the competitive immunometric assay method previously described with sample fluids containing known digoxin concentrations. The assays were carried out on an automated laboratory instrument. The enzyme label used in the conjugate was methyl umbelliferyl phosphate and the readout signal was obtained by directed 360 nm radiation upon the bottom surface of the solid support and measuring the reflected 450 nm radiation. The signals obtained are shown in Table I. The assays were read kinetically and the signals obtained are the slopes of the kinetic measurements. Each value shown in Table I is the average of three replicates.
Table
It can be seen that the assay method of the invention provided high signal levels and a desirable steep standard curve slope in the assay range (about 0.5 - 4.0 ng/ml).
EXAMPLE II A coating solution was prepared which was the same as that described in Example I except that it contained 0.0625 / g/ml of a monoclonal antibody to T3 instead of the anti-digoxin antibodies. Assay elements were prepared as described in Example I and used to carry out the competitive solid phase assay method previously described. The results obtained are shown in Table II. Table II
T3 (nα/ml) Signal
0.00 5973
0.50 5279
1 .00 4487 2.00 3072
4.00 1981
8.00 1220 Again the assay method of the invention provided high signal levels and a desirable steep standard curve slope in the assay range (about 0.50 - 8.00 ng/ml).
Although the invention has been described in detail with respect to various preferred embodiments, those skilled in the art will recognize^ that variations and modifications may be made therein which are within the spirit of the invention and the scope of the appended claims.

Claims

What is claimed is:
1. A solid support having an antibody of interest immobilized thereon comprising a solid support to which there is attached a complex of: (1 ) a specific monoclonal antibody of interest; (2) a nonspecific antibody; and (3) an antibody directed against the Fc fragments of said specific and nonspecific antibodies.
2. The solid support as defined in claim 1 wherein said solid support is a fibrous glass material.
3. The solid support as defined in claim 2 wherein said specific monoclonal antibody is a mouse anti-digoxin antibody or a mouse anti-triiodothyronine (T3) antibody, said nonspecific antibody is a mouse IgG antibody and said antibody directed against the Fc fragments of said specific and nonspecific antibodies is a goat anti- mouse antibody.
4. The solid support as defined in claim 1 wherein the specific antibody and the nonspecific antibody are of the same species.
5. A method for preparing a solid support having an antibody of interest immobilized thereon comprising
(a) adding to a solution containing a specific monoclonal antibody of interest and a nonspecific antibody, an antibody directed against the Fc fragments of said specific and nonspecific antibodies;
(b) incubating said solution at a temperature and for a period of time sufficient to allow said antibodies to form a complex;
(c) applying said solution to a solid support and (d) drying said solid support whereby said antibody complex is immobilized on the solid support.
6. The method as defined in claim 5 wherein said solid support is a fibrous glass material.
7. The method as defined in claim claim 5 wherein step
(b) is carried out at about 37°C for about one hour.
8. The method as defined in claim 5 wherein said specific and nonspecific antibodies are of the same species.
9. The method as defined in claim 8 wherein said specific antibody is a mouse monoclonal antibody and said nonspecific antibody is a mouse IgG antibody.
10. The method as defined in claim 9 wherein said specific antibody is a mouse anti-digoxin antibody or a mouse anti- triiodothyronine (T3) antibody.
1 1 . A competitive solid phase immunoassay method comprising
(a) contacting a solid support as defined in claim 1 with (i) a sample fluid containing an analyte which is the binding partner of the specific monoclonal antibody immobilized on said solid support and (ii) a conjugate comprising a label bound to said analyte or an analogue thereof;
(b) separating the solid and fluid phases; and
(c) detecting the amount of the label present in either the solid or fluid phase.
1 2. The method as defined in claim 1 1 wherein said label is an enzyme and step (b) is carried out by applying a substrate solution to said solid support.
13. The method as defined in claim 12 wherein the reaction of said substrate and said enzyme provides a fluorescent species.
14. The method as defined in claim 1 1 wherein step (a) is carried out by first applying said sample fluid to said solid support and then applying a solution of said conjugate to the solid support.
15. The method as defined in claim 1 1 wherein said specific monoclonal antibody immobilized on said solid support is a monoclonal anti-digoxin antibody or a monoclonal anti-triiodothyronine (T3) antibody.
■ 16. The method as defined in claim 14 wherein said specific monoclonal antibody immobilized on said solid support is a monoclonal anti-digoxin antibody or a monoclonal anti-triiodothyronine (T3) antibody.
EP19910908038 1990-05-18 1991-03-27 Solid support having antibodies immobilized thereon Withdrawn EP0483309A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US526580 1983-08-26
US52658090A 1990-05-18 1990-05-18

Publications (1)

Publication Number Publication Date
EP0483309A1 true EP0483309A1 (en) 1992-05-06

Family

ID=24097912

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19910908038 Withdrawn EP0483309A1 (en) 1990-05-18 1991-03-27 Solid support having antibodies immobilized thereon

Country Status (4)

Country Link
EP (1) EP0483309A1 (en)
JP (1) JPH05500116A (en)
CA (1) CA2039599A1 (en)
WO (1) WO1991018291A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3422993A (en) * 1992-01-06 1993-08-03 Dade International Inc. Multi-test immunochemical reagent and method to use same
CA2093494A1 (en) * 1992-04-17 1993-10-18 Keisuke Iwata Method for the elimination of non-specific reactions in immuno-assays
US5399500A (en) * 1992-06-26 1995-03-21 Becton Dickinson And Company Two step process for coating of antibodies to a solid phase
DE19505204A1 (en) * 1995-02-16 1996-08-22 Behringwerke Ag Modification of the reactivity of agglutination reagents by co-coating with substances not directed against the analyte
US20050069962A1 (en) 2001-10-12 2005-03-31 Archer Robert M Antibody complexes and methods for immunolabeling
US10604567B2 (en) 2017-03-13 2020-03-31 Intrinsic Lifesciences Llc Antibodies to human erythroferrone and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3799742A (en) * 1971-12-20 1974-03-26 C Coleman Miniaturized integrated analytical test container
US4803167A (en) * 1982-03-30 1989-02-07 The General Hospital Corporation Monoclonal antidigoxtin antibodies
US4606855A (en) * 1982-07-26 1986-08-19 Mex Research Associates C/O Leon Reimer Monoclonal antibody to digoxin
FR2556840B1 (en) * 1983-12-16 1987-12-24 Immunotech Sa PROCESS FOR THE IN VITRO ASSAY OF IMMUNOGLOBULINS SPECIFIC TO ONE OR MORE ALLERGENS AND REAGENTS AND MEANS FOR CARRYING OUT THIS METHOD
US4918025A (en) * 1987-03-03 1990-04-17 Pb Diagnostic Systems, Inc. Self contained immunoassay element
DE3718140A1 (en) * 1987-05-29 1988-12-08 Boehringer Mannheim Gmbh HETEROGENIC IMMUNOASSAY
JPS6488367A (en) * 1987-09-30 1989-04-03 Japan Chem Res Immobilized antibody

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9118291A1 *

Also Published As

Publication number Publication date
CA2039599A1 (en) 1991-11-19
JPH05500116A (en) 1993-01-14
WO1991018291A1 (en) 1991-11-28

Similar Documents

Publication Publication Date Title
US4959307A (en) Immunoseparating strip
US4594327A (en) Assay method for whole blood samples
US4879215A (en) Concentrating immunochemical test strip
JP2590059B2 (en) Chromatography apparatus and measurement method using the same
AU689174B2 (en) Sensor device for sandwich assay
US5212060A (en) Dry test strip comprising a dextran barrier for excluding erythrocytes
US5569608A (en) Quantitative detection of analytes on immunochromatographic strips
EP0259157B1 (en) Immunoseparating strip
EP0630475B1 (en) Red blood cell separation means for specific binding assays
EP0303110A2 (en) Immunodiagnostic device and method
US5260194A (en) Immunoseparating strip
JPH0627738B2 (en) Specific binding assay device and method
US5085988A (en) Immunoseparating strip
JPH08508569A (en) Opposite member chromatography assay device
US5260193A (en) Immunoseparating strip
EP0186100A2 (en) Analytical device and method for using same
EP1917529B1 (en) Analyte assaying by means of immunochromatography with lateral migration
EP0483309A1 (en) Solid support having antibodies immobilized thereon
EP0287731A2 (en) Dry test strips having a red blood cell exclusion layer
JPS63210664A (en) Dry test piece for device using oxygen demand detection system and detecting method of analytic component in fluid to be inspected
EP0253581B1 (en) Analytical element having water-soluble polymers and determinations using same
JP4437211B2 (en) Measuring method using immunochromatography and sample analysis tool used therefor
EP0940681A2 (en) Method and device for the detection of an analyte in a fluid test sample
AU647428B2 (en) Immunoassay for antibodies to infectious disease agents
CA2198948A1 (en) Quantitative detection of analytes on immunochromatographic strips

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19910906

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19921111